A study on comparative efficacy of anti tubercular chemoprophylaxis with 2 different regimens: 2 months of rifampicin and pyrazinamide and 6 months of daily isoniazid and rifampicin in HIV infected tuberculin reactors
Human immune-virus (HIV) infection is the most significant risk factor for progression of latent mycobacterium tuberculosis (MTB) infection to active tuberculosis. Tuberculosis reactivation among human immunodeficiency virus (HIV) infected cases can be prevented by anti tubercular chemoprophylaxis....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2006-01-01
|
| Series: | Lung India |
| Subjects: | |
| Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2006;volume=23;issue=2;spage=64;epage=69;aulast=Prasad |
| Summary: | Human immune-virus (HIV) infection is the most significant risk factor for progression of latent mycobacterium tuberculosis (MTB) infection to active tuberculosis. Tuberculosis reactivation among human immunodeficiency virus (HIV) infected cases can be prevented by anti tubercular chemoprophylaxis. This randomized controlled study compared the efficacy of 2 months of daily rifampicin and pyrazinamide and 6 months of daily rifampicin and isoniazid drug regimes in preventing active tuberculosis in HIV seropositives. It is observed that 2 months of daily rifampicin in combination with pyrazinamide is not only efficacious as that of 6 months of daily rifampicin and isoniazid combination in preventing active tuberculosis in HIV seropositives but has the advantage of better compliance, lesser side effects and prolonged post prophylactic preventive effect. |
|---|---|
| ISSN: | 0970-2113 0974-598X |